351 related articles for article (PubMed ID: 15153169)
21. Cost-effectiveness of screening for recurrent hepatocellular carcinoma after liver transplantation.
Ladabaum U; Cheng SL; Yao FY; Roberts JP
Clin Transplant; 2011; 25(2):283-91. PubMed ID: 20156221
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of coronary artery disease screening in asymptomatic patients with type 2 diabetes and other atherogenic risk factors in Japan: factors influencing on international application of evidence-based guidelines.
Hayashino Y; Shimbo T; Tsujii S; Ishii H; Kondo H; Nakamura T; Nagata-Kobayashi S; Fukui T
Int J Cardiol; 2007 May; 118(1):88-96. PubMed ID: 16949690
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of osteoporosis screening and treatment with hormone replacement therapy, raloxifene, or alendronate.
Mobley LR; Hoerger TJ; Wittenborn JS; Galuska DA; Rao JK
Med Decis Making; 2006; 26(2):194-206. PubMed ID: 16525173
[TBL] [Abstract][Full Text] [Related]
24. The costs and benefits of enhanced depression care to employers.
Wang PS; Patrick A; Avorn J; Azocar F; Ludman E; McCulloch J; Simon G; Kessler R
Arch Gen Psychiatry; 2006 Dec; 63(12):1345-53. PubMed ID: 17146009
[TBL] [Abstract][Full Text] [Related]
25. Endoscopic screening for gastric cancer.
Dan YY; So JB; Yeoh KG
Clin Gastroenterol Hepatol; 2006 Jun; 4(6):709-16. PubMed ID: 16765306
[TBL] [Abstract][Full Text] [Related]
26. Decision-analytical model with lifetime estimation of costs and health outcomes for one-time screening for abdominal aortic aneurysm in 65-year-old men.
Henriksson M; Lundgren F
Br J Surg; 2005 Aug; 92(8):976-83. PubMed ID: 16034844
[TBL] [Abstract][Full Text] [Related]
27. Cost-effectiveness of screening for hepatopulmonary syndrome in liver transplant candidates.
Roberts DN; Arguedas MR; Fallon MB
Liver Transpl; 2007 Feb; 13(2):206-14. PubMed ID: 17205561
[TBL] [Abstract][Full Text] [Related]
28. [Imaging in the screening and diagnosis of hepatocellular carcinoma in cirrhosis liver in Tunisia. A series of 30 cases].
Ben Hassine L; Daghfous MH; Mami A; Chammakhi-Jemli C; Zouaoui W; Saddoud W; Miaoui A; Kharrat J; Ghorbal A; Sehili-Briki S
Tunis Med; 2007 May; 85(5):421-6. PubMed ID: 17657932
[TBL] [Abstract][Full Text] [Related]
29. Cost utility of screening for Barrett's esophagus with esophageal capsule endoscopy versus conventional upper endoscopy.
Rubenstein JH; Inadomi JM; Brill JV; Eisen GM
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):312-8. PubMed ID: 17368230
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of the surveillance program of hepatocellular carcinoma depends on the medical circumstances.
Nouso K; Tanaka H; Uematsu S; Shiraga K; Okamoto R; Onishi H; Nakamura S; Kobayashi Y; Araki Y; Aoki N; Shiratori Y
J Gastroenterol Hepatol; 2008 Mar; 23(3):437-44. PubMed ID: 17683496
[TBL] [Abstract][Full Text] [Related]
31. Cost-effectiveness of extending cervical cancer screening intervals among women with prior normal pap tests.
Kulasingam SL; Myers ER; Lawson HW; McConnell KJ; Kerlikowske K; Melnikow J; Washington AE; Sawaya GF
Obstet Gynecol; 2006 Feb; 107(2 Pt 1):321-8. PubMed ID: 16449119
[TBL] [Abstract][Full Text] [Related]
32. Cost-effectiveness of sacral neuromodulation versus intravesical botulinum A toxin for treatment of refractory urge incontinence.
Siddiqui NY; Amundsen CL; Visco AG; Myers ER; Wu JM
J Urol; 2009 Dec; 182(6):2799-804. PubMed ID: 19837427
[TBL] [Abstract][Full Text] [Related]
33. The cost-effectiveness of vaccinating chronic hepatitis C patients against hepatitis A.
Jacobs RJ; Koff RS; Meyerhoff AS
Am J Gastroenterol; 2002 Feb; 97(2):427-34. PubMed ID: 11866283
[TBL] [Abstract][Full Text] [Related]
34. Cost-effectiveness of capsule endoscopy in screening for colorectal cancer.
Hassan C; Zullo A; Winn S; Morini S
Endoscopy; 2008 May; 40(5):414-21. PubMed ID: 18302080
[TBL] [Abstract][Full Text] [Related]
35. Cost-benefit analysis of capsule endoscopy compared with standard upper endoscopy for the detection of Barrett's esophagus.
Gerson L; Lin OS
Clin Gastroenterol Hepatol; 2007 Mar; 5(3):319-25. PubMed ID: 17368231
[TBL] [Abstract][Full Text] [Related]
36. A statistical model predicting high hepatocyte proliferation index and the risk of developing hepatocellular carcinoma in patients with hepatitis C virus-related cirrhosis.
Azzaroli F; Colecchia A; Lodato F; Trerè D; Bacchi Reggiani ML; Festi D; Prati GM; Accogli E; Casanova S; Derenzini M; Roda E; Mazzella G
Aliment Pharmacol Ther; 2006 Jul; 24(1):129-36. PubMed ID: 16803611
[TBL] [Abstract][Full Text] [Related]
37. Cost-effectiveness analysis of population-based screening of hepatocellular carcinoma: Comparing ultrasonography with two-stage screening.
Kuo MJ; Chen HH; Chen CL; Fann JC; Chen SL; Chiu SY; Lin YM; Liao CS; Chang HC; Lin YS; Yen AM
World J Gastroenterol; 2016 Mar; 22(12):3460-70. PubMed ID: 27022228
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness analysis of endometrial cancer prevention strategies for obese women.
Kwon JS; Lu KH
Obstet Gynecol; 2008 Jul; 112(1):56-63. PubMed ID: 18591308
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of routine childhood vaccination for hepatitis A in the United States.
Rein DB; Hicks KA; Wirth KE; Billah K; Finelli L; Fiore AE; Hoerger TJ; Bell BP; Armstrong GL
Pediatrics; 2007 Jan; 119(1):e12-21. PubMed ID: 17200237
[TBL] [Abstract][Full Text] [Related]
40. Long-term effectiveness and cost-effectiveness of screening for hepatitis C virus infection.
Sroczynski G; Esteban E; Conrads-Frank A; Schwarzer R; Mühlberger N; Wright D; Zeuzem S; Siebert U
Eur J Public Health; 2009 Jun; 19(3):245-53. PubMed ID: 19196737
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
